Thermo Fisher Scientific Inc. $TMO Shares Acquired by First Manhattan CO. LLC.

Key Points

• First Manhattan CO. LLC. increased its stake in Thermo Fisher Scientific by 6.4%, holding 948,563 shares valued at approximately $472.36 million.
• Thermo Fisher Scientific reported a quarterly EPS of $5.36, exceeding the consensus estimate, with revenue up 2.9% year-over-year at $10.86 billion.
• The company announced a quarterly dividend of $0.43 per share, with a yield of 0.3%, highlighting a low payout ratio of 9.95%.

First Manhattan CO. LLC. lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 948,563 shares of the medical research company's stock after acquiring an additional 57,242 shares during the period. Thermo Fisher Scientific accounts for approximately 1.4% of First Manhattan CO. LLC.'s portfolio, making the stock its 11th biggest holding. First Manhattan CO. LLC. owned 0.25% of Thermo Fisher Scientific worth $472,361,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in TMO. Vanguard Group Inc. boosted its stake in Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after buying an additional 230,382 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Thermo Fisher Scientific by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after buying an additional 115,463 shares during the last quarter. Pictet Asset Management Holding SA boosted its stake in Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after buying an additional 193,378 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Thermo Fisher Scientific by 11.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company's stock worth $1,259,450,000 after buying an additional 257,462 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Thermo Fisher Scientific by 9.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,419,617 shares of the medical research company's stock worth $1,204,002,000 after buying an additional 215,232 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $493.05 on Monday. The company has a market cap of $186.18 billion, a P/E ratio of 28.52, a PEG ratio of 2.63 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The business's 50-day simple moving average is $452.50 and its 200 day simple moving average is $453.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's revenue was up 2.9% on a year-over-year basis. During the same period last year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,896 shares of company stock worth $13,603,438 over the last 90 days. 0.33% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday. Hsbc Global Res lowered Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. HSBC reissued a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Barclays lifted their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.